Vectura Group (OTCMKTS:VEGPF) and Dova Pharmaceuticals (NASDAQ:DOVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.
Valuation & Earnings
This table compares Vectura Group and Dova Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dova Pharmaceuticals||$10.35 million||43.84||-$72.28 million||($2.60)||-6.18|
This table compares Vectura Group and Dova Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
30.2% of Dova Pharmaceuticals shares are held by institutional investors. 60.3% of Dova Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Vectura Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Dova Pharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Vectura Group and Dova Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dova Pharmaceuticals has a consensus price target of $27.86, suggesting a potential upside of 73.35%. Given Dova Pharmaceuticals’ higher possible upside, analysts plainly believe Dova Pharmaceuticals is more favorable than Vectura Group.
Dova Pharmaceuticals beats Vectura Group on 6 of the 9 factors compared between the two stocks.
Vectura Group Company Profile
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.